A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.

MLA

Oudard, Stéphane, et al. “A Phase II Study of the Cancer Vaccine TG4010 Alone and in Combination with Cytokines in Patients with Metastatic Renal Clear-Cell Carcinoma: Clinical and Immunological Findings.” Cancer Immunology, Immunotherapy : CII, vol. 60, no. 2, Feb. 2011, pp. 261–71. EBSCOhost, https://doi.org/10.1007/s00262-010-0935-9.

APA

Oudard, S., Rixe, O., Beuselinck, B., Linassier, C., Banu, E., Machiels, J.-P., Baudard, M., Ringeisen, F., Velu, T., Lefrere-Belda, M.-A., Limacher, J.-M., Fridman, W. H., Azizi, M., Acres, B., & Tartour, E. (2011). A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunology, Immunotherapy : CII, 60(2), 261–271. https://doi.org/10.1007/s00262-010-0935-9

Chicago

Oudard, Stéphane, Olivier Rixe, Benoit Beuselinck, Claude Linassier, Eugeniu Banu, Jean-Pascal Machiels, Marion Baudard, et al. 2011. “A Phase II Study of the Cancer Vaccine TG4010 Alone and in Combination with Cytokines in Patients with Metastatic Renal Clear-Cell Carcinoma: Clinical and Immunological Findings.” Cancer Immunology, Immunotherapy : CII 60 (2): 261–71. doi:10.1007/s00262-010-0935-9.